Intergeneric poliovirus recombinants for the treatment of malignant glioma
AUTOR(ES)
Gromeier, Matthias
FONTE
National Academy of Sciences
RESUMO
Poliovirus neuropathogenicity depends on sequences within the 5′ nontranslated region of the virus. Exchange of the poliovirus internal ribosomal entry site with its counterpart from human rhinovirus type 2 resulted in attenuation of neurovirulence in primates. Despite deficient virus propagation in cells of neuronal origin, nonpathogenic polio recombinants retain excellent growth characteristics in cell lines derived from glial neoplasms. Susceptibility of malignant glioma cells to poliovirus may be mediated by expression of a poliovirus receptor, CD155, in glial neoplasms. Intergeneric polio recombinants with heterologous internal ribosomal entry site elements unfolded strong oncolytic potential against experimentally induced gliomas in athymic mice. Our observations suggest that highly attenuated poliovirus recombinants may have applicability as biotherapeutic antineoplastic agents.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=18745Documentos Relacionados
- Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.
- Interstitial radiotherapy for malignant glioma.
- Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
- Meningioma after contralateral hemispherectomy for malignant glioma: case report.
- Malignant glioma in laboratory workers.
